Generics

Former Bristol Myers Squibb executive Bill Szablewski will serve as head of capital markets for Viatris, the company being created by the merger of Mylan and Pfizer's Upjohn.

The combination of Mylan and Pfizer's Upjohn business is expected to close on Nov. 16, at which time the combined company will be renamed Viatris.

Zydus Cadila’s linagliptin tablets will be available in a dosage strength of 5 mg, pending the Food and Drug Administration's final approval.

Tavaborole topical solution had a market value of roughly $82 million and fenofibrate capsules had a market value of $17 million, for the 12 months ended June 2020.

Zydus Cadila's generic Xeljanz XR tablets provide a once-daily treatment for adult patients with moderately to severely active ulcerative colitis.

Proceeds from Aurobindo's divestiture of Natrol will be used to reduce debt and develop other new strategic initiatives, according to the company.

Schuyler VanWinkle has been recognized by Cardinal Health as Generic Trade Representative of the Year for the second time in three years.

The FDA has granted approval for Zydus Cadila's generic Proventil, and generic Vesicare.